STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Passive 11.95% Stake by Wellington in Structure Therapeutics (GPCR)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Wellington Management disclosed beneficial ownership of 20,627,307 shares of Structure Therapeutics common stock, representing 11.95% of the class. The filing shows no sole voting or dispositive power and reports shared voting power of 19,646,661 and shared dispositive power of 20,627,307, indicating these securities are managed jointly across Wellington entities. The shares are owned of record by clients of Wellington Investment Advisers rather than by Wellington as principal.

The filing also states the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. One named client, Vanguard Health Care Fund, is identified as an exception to the general statement about clients.

Positive

  • Material disclosure of stake: Wellington reports ownership of 20,627,307 shares (11.95%), a clearly quantified, material position.
  • Clear voting/dispositive breakdown: Filing provides specific shared voting power (19,646,661) and shared dispositive power (20,627,307), improving transparency.
  • Passive intent certified: The statement certifies holdings are in the ordinary course of business and not held to change or influence control.

Negative

  • Client exception noted: The filing names Vanguard Health Care Fund as an exception but does not quantify that client’s percentage, reducing clarity on single-client concentration.
  • No sole control: The reporting entities state zero sole voting or dispositive power, meaning Wellington does not exercise individual control despite the large aggregate stake.

Insights

TL;DR: Wellington reports a material, approximately 12% passive stake in Structure Therapeutics, disclosed as shared voting and dispositive power.

Wellington Management Group and related entities together report beneficial ownership of 20,627,307 shares (11.95%) with shared voting power of 19,646,661. The Schedule 13G classification and the signed certification indicate a passive, non-control intent, which typically signals confidence by large asset managers without an activist agenda. For investors, the holding is material in size and could affect float and liquidity analyses, but the filing contains no indication of plans to change governance or strategy.

TL;DR: A sizable passive stake is disclosed; governance impact appears limited because the filer certifies no intent to influence control.

The report clarifies that ownership is through clients of Wellington Investment Advisers and that there is no sole voting or dispositive power reported. While the position is material at 11.95% of the class, the explicit certification that the shares are held in the ordinary course and not to influence control suggests limited immediate governance engagement. Notably, the filing identifies Vanguard Health Care Fund as an exception where a client may have separate significance, which should be tracked by stakeholders seeking clarity on shareholder composition.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025

FAQ

How many shares of GPCR does Wellington report owning?

Wellington reports beneficial ownership of 20,627,307 shares, representing 11.95% of the class.

Does Wellington have sole voting or dispositive power over these GPCR shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power, with shared voting power of 19,646,661 and shared dispositive power of 20,627,307.

Which Wellington entities filed this Schedule 13G/A for GPCR?

The filing names Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP as reporting persons.

Is Wellington seeking to influence control of Structure Therapeutics (GPCR)?

No. The filing includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control.

Who holds the securities of record according to the filing?

The securities are owned of record by clients of the Wellington Investment Advisers, not Wellington as principal; the filing notes Vanguard Health Care Fund as a named exception.
Structure Therapeutics Inc ADR

NASDAQ:GPCR

GPCR Rankings

GPCR Latest News

GPCR Latest SEC Filings

GPCR Stock Data

2.08B
57.80M
3.04%
98.22%
12.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO